Pliant Therapeutics (PLRX) Liabilities and Shareholders Equity (2019 - 2026)

Pliant Therapeutics (PLRX) has 8 years of Liabilities and Shareholders Equity data on file, last reported at $202.6 million in Q1 2026.

• Liabilities and Shareholders Equity for Q1 2026 came in at $202.6 million, down 41.24% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.0 billion (down 39.91% YoY), and the FY2025 annual result was $225.2 million, down 43.26% from the prior year.
• Liabilities and Shareholders Equity declined to $202.6 million in Q1 2026 per PLRX's latest filing, from $225.2 million in the prior quarter.
• Over five years, Liabilities and Shareholders Equity peaked at $597.9 million in Q1 2023 and troughed at $184.6 million in Q2 2022.
• A 5-year average of $384.2 million and a median of $377.2 million in 2022 frame the typical range for Liabilities and Shareholders Equity.
• The sharpest annual moves came in 2023 and 2025: Liabilities and Shareholders Equity jumped 211.39% in 2023, then slumped 43.26% in 2025.
• A 5-year view of Liabilities and Shareholders Equity shows it stood at $350.6 million in 2022, then surged by 46.07% to $512.2 million in 2023, then fell by 22.49% to $396.9 million in 2024, then tumbled by 43.26% to $225.2 million in 2025, then declined by 10.05% to $202.6 million in 2026.
• Business Quant data shows PLRX's Liabilities and Shareholders Equity at $202.6 million in Q1 2026, $225.2 million in Q4 2025, and $276.6 million in Q3 2025.